Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alicaforsen · 4 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Alicaforsen | DRUG | - |
Inclusion Criteria 1. Age \>/= 12 years 2. Weight \>/= 36 kg 3. CDAI score of 220 - 400 4. Documentation of Crohn's disease activity by endoscopy, biopsy or imaging in the last 2 years 5. No TNF-α inhibitor treatment for three months prior to first study drug infusion Exclusion Criteria 1. Known ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Alicaforsen is an investigational small molecule being developed for gastrointestinal conditions, specifically Crohn's Disease and Ulcerative Colitis. It has been studied in patients with active Crohn's Disease and in patients with mild to moderate active Ulcerative Colitis. The drug is not approved and remains in clinical development.
Alicaforsen is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker IONS. Ionis has conducted clinical trials of Alicaforsen in Crohn's Disease and Ulcerative Colitis.
Alicaforsen has completed Phase 3 clinical trials for Crohn's Disease. It has also completed Phase 2 trials for Ulcerative Colitis. The drug is investigational and not FDA approved. No active trials are currently listed for Alicaforsen.
Alicaforsen has been studied in two completed Phase 3 trials for Crohn's Disease: NCT00048113 and NCT00048295, each enrolling 150 patients. It was also studied in two completed Phase 2 trials for Ulcerative Colitis: NCT00063414 and NCT00063830. All trials are completed.
Yes, Alicaforsen is also known as ISIS 2302. Clinical trial records refer to the drug by both names, for example in the Phase 3 trial titled 'Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease'.
Alicaforsen has been evaluated in two completed Phase 2 clinical trials for mild to moderate active Ulcerative Colitis. These trials were conducted in the United States and included adult patients. The drug remains investigational for this indication.